Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
Acquires Rights from UCSD to Develop Cysteamine for the Treatment of NASH
25-Mar-2008 -
Raptor Pharmaceuticals Corp. announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc., has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego ("UCSD") around the use of Cysteamine, and Delayed Release Cysteamine ("DR ...
cirrhosis
clinical trials
cystinosis
+5